MML Investors Services LLC Sells 51,063 Shares of Candel Therapeutics, Inc. (NASDAQ:CADL)

MML Investors Services LLC decreased its holdings in Candel Therapeutics, Inc. (NASDAQ:CADL) by 69.6% during the 3rd quarter, HoldingsChannel reports. The firm owned 22,313 shares of the company’s stock after selling 51,063 shares during the quarter. MML Investors Services LLC’s holdings in Candel Therapeutics were worth $155,000 at the end of the most recent reporting period.

Other institutional investors also recently modified their holdings of the company. Bank of New York Mellon Corp acquired a new position in Candel Therapeutics during the 2nd quarter worth approximately $338,000. Cubist Systematic Strategies LLC bought a new stake in shares of Candel Therapeutics during the second quarter worth $162,000. Rhumbline Advisers bought a new stake in shares of Candel Therapeutics during the second quarter worth $143,000. State Street Corp increased its holdings in shares of Candel Therapeutics by 4.1% during the third quarter. State Street Corp now owns 492,005 shares of the company’s stock worth $3,410,000 after buying an additional 19,207 shares in the last quarter. Finally, Atom Investors LP bought a new position in shares of Candel Therapeutics in the 3rd quarter valued at $103,000. Institutional investors and hedge funds own 13.93% of the company’s stock.

Analyst Ratings Changes

Separately, HC Wainwright restated a “buy” rating and set a $19.00 price objective (up previously from $11.00) on shares of Candel Therapeutics in a research report on Wednesday, December 18th.

Candel Therapeutics Stock Performance

Candel Therapeutics stock opened at $8.87 on Friday. The business has a 50 day moving average of $5.75 and a 200-day moving average of $6.10. The company has a market capitalization of $288.06 million, a P/E ratio of -5.13 and a beta of -0.95. Candel Therapeutics, Inc. has a 1 year low of $1.16 and a 1 year high of $14.60. The company has a debt-to-equity ratio of 1.66, a current ratio of 1.18 and a quick ratio of 1.18.

Insiders Place Their Bets

In other Candel Therapeutics news, major shareholder Estuardo Aguilar-Cordova sold 15,000 shares of the business’s stock in a transaction that occurred on Monday, October 14th. The stock was sold at an average price of $6.02, for a total value of $90,300.00. Following the transaction, the insider now directly owns 929,873 shares of the company’s stock, valued at approximately $5,597,835.46. The trade was a 1.59 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Paul B. Manning purchased 1,250,000 shares of Candel Therapeutics stock in a transaction on Monday, December 16th. The stock was bought at an average price of $6.00 per share, with a total value of $7,500,000.00. Following the completion of the acquisition, the director now directly owns 1,303,752 shares of the company’s stock, valued at approximately $7,822,512. This trade represents a 2,325.49 % increase in their position. The disclosure for this purchase can be found here. Insiders have sold 66,127 shares of company stock valued at $349,911 in the last ninety days. 41.60% of the stock is currently owned by insiders.

Candel Therapeutics Profile

Candel Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma.